Tasly Pharmaceuticals, Inc. is positioned to become a world-renowned innovator in pharmaceuticals, biologics, and nutraceuticals.

Update

Highlights

Cardiovascular (T89) Drug Clinical Studies

Dantonic® is a modern and industrialized botanical drug formula which features Danshen (Radix Salviae Miltiorrhizae, RSM) and Sanqi (Radix Notoginseng, RN) as active ingredients and Borneol as an absorption enhancer. Dantonic® was approved as a prescription drug for the treatment of chronic stable angina pectoris in patients with coronary heart disease by the State Food and Drug Administration of China (CFDA) in 1993.  Learn more.

A randomized controlled trial to confirm the antianginal effect of T89 in patients with stable ischemic heart disease (ORESA): Rationale and design
Confirmative Phaselll Global Clinical Trial of a Botanical Drug in Patients with Chronic Stable Angina (CAESA): New Treatment Options for Myocardial Ischemia Heart Disease
Synergism of Chinese Herbal Medicine: Illustrated by Danshen Compound
T89 Phase II Study & T89 Phase III Study
Reduction of body fat and improved lipid profile associated with daily consumption of a Puer tea extract in a hyperlipidemic population: a randomized placebo-controlled trial